Meritage Pharma is committed to the development of prescription products based on safe and effective molecules for the treatment of gastrointestinal and atopic diseases. Meritage Pharma’s initial product candidate is intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the esophagus.

Publications show all

Meritage Pharma has published 1 articles.

Patents show all

46Applications11Issued

Clinical Trials show all

1Phase 2

SEC Filings show all

D3

Private Funding Events

DateOfferedSoldType
2011-11-16$7,500,002$6,500,002Equity
2009-08-27$29,972,053$29,972,053Equity
2008-12-15UnknownUnknownOther (Paper Filing)

Contact Information

    Key Executives

    • Elaine M. Phillips, Ph.D.
      Executive Officer, Director
    • Cam L. Garner
      Director
    • James C. Blair, Ph.D.
      Director
    • Kenneth J. Widder, M.D.
      Director
    • Adam K. Simpson
      Executive Officer
    • Malcolm R. Hill
      Executive Officer